21098-05-5Relevant academic research and scientific papers
Benzisothiazole compound and preparation method thereof and purpose of benzisothiazole compound for treating depression
-
Paragraph 0054; 0056; 0064; 0065, (2018/09/12)
The invention discloses a benzisothiazole compound and a preparation method thereof and a purpose of the benzisothiazole compound for treating depression. The benzisothiazole compound has a structureshown as a formula I. The research found that the compound in the formula I or its medicinal salt has the following good medicine properties of 5-HT1A acceptor excitement and 5-HT/NE reuptake inhibition effect, and has strong and rapid anti-depression effect in an animal depression model. The research result shows that the compound shown in the formula I or its medicinal salt can be used for treating depression. The invention provides an effective technical means for efficiently and rapidly treating the depression.
Synthesis and structure-activity relationship of fluoro analogues of 8-{2-[4-(4-methoxyphenyl)piperazin-1yl]ethyl}-8-azaspiro[4.5]decane-7,9-dione as selective α1d-adrenergic receptor antagonists
Konkel, Michael J.,Wetzel, John M.,Cahir, Marie,Craig, Douglas A.,Noble, Stewart A.,Gluchowski, Charles
, p. 3076 - 3079 (2007/10/03)
We have discovered high-affinity antagonists (exemplified by 11 and 12) that are the most selective for α1d-adrenergic receptors (α1d-AR) reported to date. In cloned receptor assay systems, 12 displays at least 95-fold selectivity fo
Compounds specific for the human alpha1d adrenergic receptor and uses thereof
-
, (2008/06/13)
This invention is directed towards a method of inhibiting activation of a human α1d adrenergic receptor which comprises contacting the receptor with a compound so as to inhibit activation of the receptor, wherein the compound binds selectively to a human ald adrenergic receptor. This invention provides for a compound which binds selectively to a human α1d adrenergic receptor. The invention further provides a pharmaceutical composition comprising a therapeutically effective amount of the above-defined compounds and a pharmaceutically acceptable carrier. This invention further provides for a method of treating a subject afflicted with a disease which is susceptible to treatment by antagonism of the human α1d adrenergic receptor which comprises administering to the subject an amount of the above defined compounds effective to treat the disease.
